WO2024200719 - COMPOSITION FOR USE
National phase entry is expected:
Publication Number
WO/2024/200719
Publication Date
03.10.2024
International Application No.
PCT/EP2024/058601
International Filing Date
28.03.2024
Title **
[English]
COMPOSITION FOR USE
[French]
COMPOSITION DESTINÉE À UN USAGE PARTICULIER
Applicants **
SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Avenue Nestlé 55
1800 Vevey, CH
Inventors
DOGRA, Shaillay Kumar
Appartement No 404
Le Grand Chemin 138
1066 Epalinges, CH
SAKWINSKA, Olga
Chemin de Noirmont 11
1004 Lausanne, CH
FERRIER, Laurent
Chemin du Moléson 19
1077 Servion, CH
Priority Data
23165376.7
30.03.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1134 | |
| EPO | Filing, Examination | 4697 | |
| Japan | Filing | 538 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4435 |
Total: 11379 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention provides methods for identifying an infant or young child at risk of stunted growth and compositions for use in preventing and/or treating stunted growth in an infant or young child.[French]
La présente invention concerne des procédés d'identification d'un nourrisson ou d'un enfant en bas âge présentant un risque de retard de croissance et des compositions destinées à être utilisées dans la prévention et/ou le traitement d'un retard de croissance chez un nourrisson ou un enfant en bas âge.